EP4028033A4 - Compositions et procédés de reprogrammation de tcr à l'aide de protéines de fusion - Google Patents

Compositions et procédés de reprogrammation de tcr à l'aide de protéines de fusion Download PDF

Info

Publication number
EP4028033A4
EP4028033A4 EP20862242.3A EP20862242A EP4028033A4 EP 4028033 A4 EP4028033 A4 EP 4028033A4 EP 20862242 A EP20862242 A EP 20862242A EP 4028033 A4 EP4028033 A4 EP 4028033A4
Authority
EP
European Patent Office
Prior art keywords
compositions
methods
fusion proteins
reprogramming
tcr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20862242.3A
Other languages
German (de)
English (en)
Other versions
EP4028033A1 (fr
Inventor
Patrick Baeuerle
Robert Hofmeister
Daniel Getts
Dario Gutierrez
Philippe KIEFFER-KWON
Julie DONAGHEY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TCR2 Therapeutics Inc
Original Assignee
TCR2 Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TCR2 Therapeutics Inc filed Critical TCR2 Therapeutics Inc
Publication of EP4028033A1 publication Critical patent/EP4028033A1/fr
Publication of EP4028033A4 publication Critical patent/EP4028033A4/fr
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0636T lymphocytes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/461Cellular immunotherapy characterised by the cell type used
    • A61K39/4611T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/463Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632T-cell receptors [TCR]; antibody T-cell receptor constructs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/464Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643Vertebrate antigens
    • A61K39/4644Cancer antigens
    • A61K39/464402Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411Immunoglobulin superfamily
    • A61K39/464412CD19 or B4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/7051T-cell receptor (TcR)-CD3 complex
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90Stable introduction of foreign DNA into chromosome
    • C12N15/902Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/26Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48Blood cells, e.g. leukemia or lymphoma
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/50Fusion polypeptide containing protease site
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/20Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00Genetically modified cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/15011Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041Use of virus, viral particle or viral elements as a vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP20862242.3A 2019-09-12 2020-09-11 Compositions et procédés de reprogrammation de tcr à l'aide de protéines de fusion Pending EP4028033A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962899563P 2019-09-12 2019-09-12
US202062971682P 2020-02-07 2020-02-07
PCT/US2020/050503 WO2021050948A1 (fr) 2019-09-12 2020-09-11 Compositions et procédés de reprogrammation de tcr à l'aide de protéines de fusion

Publications (2)

Publication Number Publication Date
EP4028033A1 EP4028033A1 (fr) 2022-07-20
EP4028033A4 true EP4028033A4 (fr) 2023-10-04

Family

ID=74866684

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20862242.3A Pending EP4028033A4 (fr) 2019-09-12 2020-09-11 Compositions et procédés de reprogrammation de tcr à l'aide de protéines de fusion

Country Status (10)

Country Link
EP (1) EP4028033A4 (fr)
JP (1) JP2022548866A (fr)
KR (1) KR20220078607A (fr)
CN (1) CN114828862A (fr)
AU (1) AU2020344628A1 (fr)
BR (1) BR112022004458A2 (fr)
CA (1) CA3154287A1 (fr)
IL (1) IL291236A (fr)
MX (1) MX2022002984A (fr)
WO (1) WO2021050948A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023091420A2 (fr) * 2021-11-16 2023-05-25 TCR2 Therapeutics Inc. Compositions et méthodes pour modification de lymphocytes t
WO2023133296A2 (fr) * 2022-01-07 2023-07-13 Sorrento Therapeutics, Inc. Récepteurs de lymphocytes t gamma delta ciblant pd-l1 modifiés
WO2024039576A2 (fr) * 2022-08-19 2024-02-22 Memorial Sloan-Kettering Cancer Center Récepteurs de lymphocytes t ciblant des mutations ras et utilisations associées

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017158116A1 (fr) * 2016-03-16 2017-09-21 Immatics Biotechnologies Gmbh Lymphocytes t transfectés et récepteurs de lymphocytes t destinés à être utilisés en immunothérapie contre des cancers
WO2019118508A1 (fr) * 2017-12-12 2019-06-20 The Trustees Of The University Of Pennsylvania Cellules immunitaires génétiquement modifiées ciblant ny-eso-1 et leurs procédés d'utilisation
WO2019133443A1 (fr) * 2017-12-28 2019-07-04 Janux Therapeutics, Inc. Récepteurs de lymphocytes t modifiés

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9181527B2 (en) * 2009-10-29 2015-11-10 The Trustees Of Dartmouth College T cell receptor-deficient T cell compositions
CN107858332A (zh) * 2011-10-28 2018-03-30 瑞泽恩制药公司 T细胞受体基因修饰小鼠
SG10201913247XA (en) * 2015-10-23 2020-02-27 Eureka Therapeutics Inc Antibody/t-cell receptor chimeric constructs and uses thereof
EP3445787B1 (fr) * 2016-10-07 2020-12-02 TCR2 Therapeutics Inc. Composés et méthodes pour la reprogrammation de récepteurs des cellules t par des protéines chimériques
CA3044593A1 (fr) * 2016-11-22 2018-05-31 TCR2 Therapeutics Inc. Compositions et methodes de reprogrammation de tcr au moyen de proteines de fusion
US20210187022A1 (en) * 2016-12-21 2021-06-24 TCR2 Therapeutics Inc. Engineered t cells for the treatment of cancer
WO2018232020A1 (fr) * 2017-06-13 2018-12-20 TCR2 Therapeutics Inc. Compositions et méthodes de reprogrammation de tcr au moyen de protéines de fusion
EA202092093A1 (ru) * 2018-03-09 2021-06-28 Тср2 Терапьютикс Инк. Композиции и способы перепрограммирования tcr с применением слитых белков

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017158116A1 (fr) * 2016-03-16 2017-09-21 Immatics Biotechnologies Gmbh Lymphocytes t transfectés et récepteurs de lymphocytes t destinés à être utilisés en immunothérapie contre des cancers
WO2019118508A1 (fr) * 2017-12-12 2019-06-20 The Trustees Of The University Of Pennsylvania Cellules immunitaires génétiquement modifiées ciblant ny-eso-1 et leurs procédés d'utilisation
WO2019133443A1 (fr) * 2017-12-28 2019-07-04 Janux Therapeutics, Inc. Récepteurs de lymphocytes t modifiés

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANNA CAPSOMIDIS ET AL: "Chimeric Antigen Receptor-Engineered Human Gamma Delta T Cells: Enhanced Cytotoxicity with Retention of Cross Presentation", MOLECULAR THERAPY, vol. 26, no. 2, 1 February 2018 (2018-02-01), US, pages 354 - 365, XP055590617, ISSN: 1525-0016, DOI: 10.1016/j.ymthe.2017.12.001 *
See also references of WO2021050948A1 *

Also Published As

Publication number Publication date
BR112022004458A2 (pt) 2022-05-31
CN114828862A (zh) 2022-07-29
EP4028033A1 (fr) 2022-07-20
KR20220078607A (ko) 2022-06-10
MX2022002984A (es) 2022-06-16
IL291236A (en) 2022-05-01
CA3154287A1 (fr) 2021-03-18
AU2020344628A1 (en) 2022-04-07
JP2022548866A (ja) 2022-11-22
WO2021050948A1 (fr) 2021-03-18

Similar Documents

Publication Publication Date Title
EP3959322A4 (fr) Compositions et méthodes de reprogrammation de tcr faisant appel à des protéines de fusion
EP3765039A4 (fr) Compositions et procédés de reprogrammation de tcr faisant appel à des protéines de fusion
EP3827013A4 (fr) Compositions et procédés de reprogrammation de tcr faisant appel à des protéines de fusion spécifiques cibles
EP3298033A4 (fr) Compositions et méthodes de reprogrammation de tcr au moyen de protéines de fusion
GB2564823B (en) Compositions and methods for TCR reprogramming using fusion proteins
EP3802812A4 (fr) Compositions de protéines de fusion ciblant l'arn et méthodes d'utilisation
EP3788068A4 (fr) Protéines de fusion de l'interleukine 15, et compositions et procédés thérapeutiques associés
SG11202101811VA (en) Compositions and methods for tcr reprogramming using fusion proteins
EP3880814A4 (fr) Protéine de fusion
EP4028033A4 (fr) Compositions et procédés de reprogrammation de tcr à l'aide de protéines de fusion
EP3735420A4 (fr) Protéines de fusion anticorps-cytosine désaminase à domaine unique
IL279541A (en) A novel binding protein specific for CD137 and PD-L1
EP3941494A4 (fr) Compositions et méthodes de reprogrammation de tcr faisant appel à des protéines de fusion
EP3919517A4 (fr) Protéine de fusion tcr et cellule exprimant une protéine de fusion tcr
EP3757218A4 (fr) Protéine hybride
EP3950720A4 (fr) Protéine de fusion et son utilisation
EP3858866A4 (fr) Protéine de fusion glp1-fc et conjugué associé
EP4146233A4 (fr) Compositions et procédés pour la reprogrammation de tcr au moyen de protéines de fusion spécifiques cd70
EP4034570A4 (fr) Protéines hétérodimères
EP4023679A4 (fr) Protéine de fusion ciblant pd-l1 et tgf-beta et son utilisation
EP4034565A4 (fr) Protéines chimériques ciblées pd-l1 et leurs utilisations
EP3999549A4 (fr) Protéines de fusion à anticorps anti-pdl1 et à sialidase et leurs méthodes d'utilisation
EP3994180A4 (fr) Protéines de fusion d'anticorps-her2-sialidase et leurs procédés d'utilisation
EP3976767A4 (fr) Compositions et procédé pour la reprogrammation cellulaire
EP3801605A4 (fr) Formulation de protéine de fusion stable

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220329

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40076974

Country of ref document: HK

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230523

A4 Supplementary search report drawn up and despatched

Effective date: 20230906

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 15/90 20060101ALI20230831BHEP

Ipc: C12N 15/113 20100101ALI20230831BHEP

Ipc: A61P 35/00 20060101ALI20230831BHEP

Ipc: A61K 39/00 20060101ALI20230831BHEP

Ipc: C12N 15/62 20060101ALI20230831BHEP

Ipc: C12N 5/0783 20100101ALI20230831BHEP

Ipc: C07K 14/725 20060101ALI20230831BHEP

Ipc: A61K 35/17 20150101AFI20230831BHEP